# Blinatumomab for minimal residual disease in adults w lymphoblastic leukemia

Blood

131, 1522-1531

DOI: 10.1182/blood-2017-08-798322

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | â€œSociety of Hematologic Oncology (SOHO) State of the Art Updates and Next Questionsâ€â€”Treatment of ALL. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 301-310. | 0.4 | 6 |
| 2 | Bispecific antibodies in haematological malignancies. Cancer Treatment Reviews, 2018, 65, 87-95. | 7.7 | 55 |
| 3 | Blinatumomab for MRD+ B-ALL: the evidence strengthens. Blood, 2018, 131, 1497-1498. | 1.4 | 6 |
| 4 | Blinatumomab facilitates complete responses. Nature Reviews Clinical Oncology, 2018, 15, 200-200. | 27.6 | 3 |
| 5 | Age matters in <scp>ALL</scp>. British Journal of Haematology, 2018, 181, 429-430. | 2.5 | 0 |
| 6 | An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia. International Journal of Hematologic Oncology, 2018, 7, IJH06. | 1.6 | 3 |
| 7 | Molecular landscape and targeted therapy of acute myeloid leukemia. Biomarker Research, 2018, 6, 32. | 6.8 | 24 |
| 8 | Toward the potential cure of leukemias in the next decade. Cancer, 2018, 124, 4301-4313. | 4.1 | 36 |
| 9 | New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 3504-3519. | 1.6 | 67 |
| 10 | Should immunologic strategies be incorporated into frontline ALL therapy?. Best Practice and Research in Clinical Haematology, 2018, 31, 367-372. | 1.7 | 2 |
| 11 | Is it time to routinely incorporate MRD into practice?. Best Practice and Research in Clinical Haematology, 2018, 31, 396-400. | 1.7 | 7 |
| 13 | Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia. Blood and Lymphatic Cancer: Targets and Therapy, 2018, Volume 8, 47-61. | 2.7 | 21 |
| 14 | Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia. Expert Review of Hematology, 2018, 11, 945-956. | 2.2 | 8 |
| 15 | Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date. Patient Related Outcome Measures, 2018, Volume 9, 329-337. | 1.2 | 16 |
| 16 | A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Acta Haematologica, 2018, 140, 209-214. | 1.4 | 4 |
| 17 | Eliminating MRD â€” FDA approval of blinatumomab for B-ALL in complete remission. Nature Reviews Clinical Oncology, 2018, 15, 727-728. | 27.6 | 10 |
| 18 | Antibody-based therapies in patients with acute lymphoblastic leukemia. Hematology American Society of Hematology Education Program, 2018, 2018, 9-15. | 2.5 | 22 |
| 19 | New drugs for acute myeloid leukemia inspired by genomics and when to use them. Hematology American Society of Hematology Education Program, 2018, 2018, 45-50. | 2.5 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 20 | Prevention and treatment of relapse after stem cell transplantation with immunotherapy. Bone Marrow Transplantation, 2018, 53, 664-672. | 2.4 | 11 |
| 21 | Tracking Down and Interrogating Cancerâ€™s Holdouts. Cell, 2018, 173, 1309. | 28.9 | 0 |
| 23 | A survey of mobile technology usage and desires by caregivers of children with cancer. Pediatric Blood and Cancer, 2018, 65, e27359. | 1.5 | 25 |
| 24 | Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia; Current Evidence, and Improving Outcomes Going Forward. Current Hematologic Malignancy Reports, 2018, 13, 329-340. | 2.3 | 19 |
| 25 | Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. Frontiers in Oncology, 2018, 8, 285. | 2.8 | 89 |
| 26 | Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?. Blood, 2018, 132, 351-361. | 1.4 | 82 |
| 27 | Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia. JAMA Oncology, 2018, 4, 1413. | 7.1 | 69 |
| 28 | Cross-sectional physician survey on the use of minimal residual disease testing in the management of pediatric and adult patients with acute lymphoblastic leukemia. Hematology, 2019, 24, 70-78. | 1.5 | 6 |
| 29 | Cancer immune therapy for lymphoid malignancies: recent advances. Seminars in Immunopathology, 2019, 41, 111-124. | 6.1 | 15 |
| 30 | Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances. Frontiers in Oncology, 2019, 9, 726. | 2.8 | 85 |
| 31 | Approach to the Adult Acute Lymphoblastic Leukemia Patient. Journal of Clinical Medicine, 2019, 8, 1175. | 2.4 | 28 |
| 32 | Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). Biology of Blood and Marrow Transplantation, 2019, 25, 2388-2397. | 2.0 | 33 |
| 33 | Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer, 2019, 125, 4181-4192. | 4.1 | 61 |
| 34 | The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT. Bone Marrow Transplantation, 2019, 54, 721-726. | 2.4 | 12 |
| 35 | Advances in measurable residual disease monitoring for adult acute lymphoblastic leukemia. Advances in Cell and Gene Therapy, 2019, 2, e67. | 0.9 | 1 |
| 36 | SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 471-479. | 0.4 | 2 |
| 37 | Updates on CAR Tâ€cell therapy in Bâ€cell malignancies. Immunological Reviews, 2019, 290, 39-59. | 6.0 | 61 |
| 38 | Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia. Medicina ClÃnica (English Edition), 2019, 153, 28-34. | 0.2 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 39 | Allogeneic Stem Cell Transplantation after Salvage Inotuzumab Ozogamicin: A Happy Ending?. Biology of Blood and Marrow Transplantation, 2019, 25, e273-e274. | 2.0 | 1 |
| 40 | Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric Bâ€cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia. Pediatric Blood and Cancer, 2019, 66, e27898. | 1.5 | 22 |
| 41 | How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?. Haematologica, 2019, 104, 1532-1541. | 3.5 | 37 |
| 42 | Philadelphia chromosomeâ€positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. American Journal of Hematology, 2019, 94, 1388-1395. | 4.1 | 26 |
| 43 | How I diagnose and manage Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica, 2019, 104, 2135-2143. | 3.5 | 22 |
| 44 | The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. International Journal of Molecular Sciences, 2019, 20, 5362. | 4.1 | 29 |
| 45 | MAGIC biomarkers of acute graft-versus-host disease: Biology and clinical application. Best Practice and Research in Clinical Haematology, 2019, 32, 101111. | 1.7 | 13 |
| 46 | Recent advances on blinatumomab for acute lymphoblastic leukemia. Experimental Hematology and Oncology, 2019, 8, 28. | 5.0 | 31 |
| 47 | Can Ph-like ALL be effectively targeted?. Best Practice and Research in Clinical Haematology, 2019, 32, 101096. | 1.7 | 8 |
| 48 | Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. Journal of Hematology and Oncology, 2019, 12, 108. | 17.0 | 51 |
| 49 | Hematological malignancies and molecular targeting therapy. European Journal of Pharmacology, 2019, 862, 172641. | 3.5 | 44 |
| 50 | Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood, 2019, 134, 1351-1355. | 1.4 | 89 |
| 52 | Blinatumomab: a novel therapy for the treatment of non-Hodgkinâ€™s lymphoma. Expert Review of Hematology, 2019, 12, 909-918. | 2.2 | 7 |
| 53 | Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment. Current Oncology Reports, 2019, 21, 4. | 4.0 | 26 |
| 54 | B-cell depleting immunotherapies: therapeutic opportunities and toxicities. Expert Review of Clinical Immunology, 2019, 15, 497-509. | 3.0 | 3 |
| 55 | Blinatumomab for the treatment of acute lymphoblastic leukemia: an update. Expert Opinion on Orphan Drugs, 2019, 7, 41-46. | 0.8 | 0 |
| 56 | Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?. Current Oncology Reports, 2019, 21, 17. | 4.0 | 14 |
| 57 | Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2019, 10, 204062071984949. | 2.5 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 58 | Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery, 2019, 18, 585-608. | 46.4 | 755 |
| 59 | Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs. Expert Opinion on Biological Therapy, 2019, 19, 707-720. | 3.1 | 10 |
| 60 | Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors. Clinical Cancer Research, 2019, 25, 6026-6034. | 7.0 | 50 |
| 61 | Recent advances in the treatment of acute lymphoblastic leukemia. Leukemia and Lymphoma, 2019, 60, 2606-2621. | 1.3 | 65 |
| 62 | The clinical study on treatment of CD19â€directed chimeric antigen receptorâ€modified T cells in a case of refractory Richter syndrome. Cancer Medicine, 2019, 8, 2930-2941. | 2.8 | 4 |
| 63 | Acute Lymphoblastic Leukemia in the Older Adult. Journal of Oncology Practice, 2019, 15, 67-75. | 2.5 | 55 |
| 64 | A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica, 2019, 104, 2028-2039. | 3.5 | 68 |
| 65 | Mechanisms of resistance to CAR T cell therapy. Nature Reviews Clinical Oncology, 2019, 16, 372-385. | 27.6 | 518 |
| 66 | Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. Lancet Haematology,the, 2019, 6, e204-e216. | 4.6 | 36 |
| 67 | Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cellâ€"recruiting Antibody Optimized for Cytotoxicity and Cytokine Release. Clinical Cancer Research, 2019, 25, 3921-3933. | 7.0 | 90 |
| 68 | Recent Advances in Adult Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2019, 14, 106-118. | 2.3 | 21 |
| 69 | Multiple Myeloma: Current Advances and Future Directions. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 255-263. | 0.4 | 27 |
| 70 | Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. Journal of Clinical Oncology, 2019, 37, 770-779. | 1.6 | 64 |
| 71 | Taking a â€œBiTE out of ALLâ€: blinatumomab approval for MRD-positive ALL. Blood, 2019, 133, 1715-1719. | 1.4 | 39 |
| 72 | T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances. Journal of Cancer Research and Clinical Oncology, 2019, 145, 941-956. | 2.5 | 33 |
| 73 | Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia Research, 2019, 79, 27-33. | 0.8 | 54 |
| 74 | Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. Haematologica, 2019, 104, e244-e247. | 3.5 | 52 |
| 75 | Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2019, 12, 15. | 17.0 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 76 | Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. Immunotherapy, 2019, 11, 373-378. | 2.0 | 22 |
| 77 | Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology, 2019, 24, 337-348. | 1.5 | 48 |
| 78 | Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?. Hematology American Society of Hematology Education Program, 2019, 2019, 17-23. | 2.5 | 16 |
| 79 | Opportunities for immunotherapy in childhood acute myeloid leukemia. Blood Advances, 2019, 3, 3750-3758. | 5.2 | 25 |
| 80 | The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Advances, 2019, 3, 4034-4042. | 5.2 | 63 |
| 81 | Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. Blood Advances, 2019, 3, 2491-2498. | 5.2 | 68 |
| 82 | Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. Blood Advances, 2019, 3, 1926-1929. | 5.2 | 53 |
| 83 | Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia in first salvage. Cancer Medicine, 2019, 8, 7650-7659. | 2.8 | 8 |
| 84 | Trispecific antibodies offer a third way forward for anticancer immunotherapy. Nature, 2019, 575, 450-451. | 27.8 | 27 |
| 85 | Adult Acute Lymphoblastic Leukemia: Treatment and Management Updates. Seminars in Oncology Nursing, 2019, 35, 150951. | 1.5 | 12 |
| 86 | Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation. Frontiers in Immunology, 2019, 10, 2516. | 4.8 | 36 |
| 87 | Gezielte FrÃ¼herkennung und risikoadaptierte Therapie. Oncology Research and Treatment, 2019, 42, 2-13. | 1.2 | 0 |
| 88 | Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer and Metastasis Reviews, 2019, 38, 595-610. | 5.9 | 65 |
| 89 | Allogeneic hematopoietic cell transplantation; the current renaissance. Blood Reviews, 2019, 34, 34-44. | 5.7 | 67 |
| 90 | Meeting report: Advances in minimal residual disease testing in multiple myeloma 2018. Advances in Cell and Gene Therapy, 2019, 2, e26. | 0.9 | 19 |
| 91 | Round optimization for improved discovery of native bispecific antibodies. Methods, 2019, 154, 51-59. | 3.8 | 1 |
| 92 | Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2019, 54, 798-809. | 2.4 | 106 |
| 93 | Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. Human Vaccines and Immunotherapeutics, 2019, 15, 594-602. | 3.3 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 94 | Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. American Journal of Hematology, 2019, 94, 257-265. | 4.1 | 99 |
| 95 | Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Annals of Hematology, 2019, 98, 159-167. | 1.8 | 73 |
| 96 | FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease. Clinical Cancer Research, 2019, 25, 473-477. | 7.0 | 94 |
| 97 | Adults with Philadelphia Chromosomeâ€"Like Acute Lymphoblastic Leukemia: Considerations for Allogeneic Hematopoietic Cell Transplantation in First Complete Remission. Biology of Blood and Marrow Transplantation, 2019, 25, e41-e45. | 2.0 | 15 |
| 98 | Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction. Journal of Oncology Pharmacy Practice, 2020, 26, 200-205. | 0.9 | 3 |
| 99 | Central nervous system emergencies in haematological malignancies. British Journal of Haematology, 2020, 189, 1028-1037. | 2.5 | 0 |
| 100 | Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 1469-1472. | 2.4 | 6 |
| 101 | The Quantification of Minimal Residual Disease Preâ€•and Postâ€‹Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. Cytometry Part B - Clinical Cytometry, 2020, 98, 75-87. | 1.5 | 18 |
| 102 | Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?. Leukemia and Lymphoma, 2020, 61, 7-17. | 1.3 | 6 |
| 103 | The treatment of adolescents and young adults with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 18-26. | 1.3 | 5 |
| 104 | The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphiaâ€•negative Bâ€‹cell acute lymphoblastic leukemia is a strong predictor for survival. American Journal of Hematology, 2020, 95, 144-150. | 4.1 | 25 |
| 105 | Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies. Clinical Pharmacokinetics, 2020, 59, 463-474. | 3.5 | 11 |
| 106 | Real-world experience managing blinatumomab toxicities in adults with relapsed/refractory acute lymphoblastic leukemia. Journal of Oncology Pharmacy Practice, 2020, 26, 1080-1085. | 0.9 | 2 |
| 107 | Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosomeâ€"positive Bâ€‹precursor acute lymphoblastic leukemia. Cancer, 2020, 126, 304-310. | 4.1 | 49 |
| 108 | When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosomeâ€"positive Bâ€‹cell acute lymphoblastic leukemia. Cancer, 2020, 126, 253-255. | 4.1 | 2 |
| 109 | Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 188, 207-223. | 2.5 | 20 |
| 110 | Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science, 2020, 27, 1. | 7.0 | 1,277 |
| 111 | The minimal that kills: Why defining and targeting measurable residual disease is the â€œSine Qua Nonâ€• for further progress in management of acute myeloid leukemia. Blood Reviews, 2020, 43, 100650. | 5.7 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 112 | Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. Current Research in Translational Medicine, 2020, 68, 17-22. | 1.8 | 24 |
| 113 | The face of remission induction. British Journal of Haematology, 2020, 188, 101-115. | 2.5 | 3 |
| 114 | Bispecific antibodies in cancer immunotherapy. Current Opinion in Biotechnology, 2020, 65, 9-16. | 6.6 | 59 |
| 115 | Trial designs using realâ€world data: The changing landscape of the regulatory approval process. Pharmacoepidemiology and Drug Safety, 2020, 29, 1201-1212. | 1.9 | 133 |
| 116 | Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. Cancer, 2020, 126, 1152-1160. | 4.1 | 29 |
| 117 | Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leukemia Research, 2020, 88, 106283. | 0.8 | 32 |
| 119 | The future of cellular immunotherapy for childhood leukemia. Current Opinion in Pediatrics, 2020, 32, 13-25. | 2.0 | 13 |
| 120 | Blinatumomab vs historic standardâ€ofâ€care treatment for minimal residual disease in adults with Bâ€cell precursor acute lymphoblastic leukaemia. European Journal of Haematology, 2020, 104, 299-309. | 2.2 | 17 |
| 121 | Chemotherapy-free Treatment â€" A New Era in Acute Lymphoblastic Leukemia?. New England Journal of Medicine, 2020, 383, 1673-1674. | 27.0 | 8 |
| 122 | Dasatinibâ€"Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. New England Journal of Medicine, 2020, 383, 1613-1623. | 27.0 | 279 |
| 123 | The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia. , 2020, 8, e000810. | | 5 |
| 124 | Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse. Expert Review of Anticancer Therapy, 2020, 20, 879-891. | 2.4 | 2 |
| 125 | Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia. JAMA Oncology, 2020, 6, 1890. | 7.1 | 207 |
| 126 | Bispecific antibodies in acute lymphoblastic leukemia therapy. Expert Review of Hematology, 2020, 13, 1211-1233. | 2.2 | 4 |
| 128 | Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2020, 61, 2767-2770. | 1.3 | 14 |
| 129 | Monoclonal antibodies in frontline acute lymphoblastic leukemia. Best Practice and Research in Clinical Haematology, 2020, 33, 101226. | 1.7 | 3 |
| 130 | Recent updates for antibody therapy for acute lymphoblastic leukemia. Experimental Hematology and Oncology, 2020, 9, 33. | 5.0 | 14 |
| 131 | Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease. Seminars in Hematology, 2020, 57, 157-163. | 3.4 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 132 | Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy . Blood and Lymphatic Cancer: Targets and Therapy, 2020, Volume 10, 7-20. | 2.7 | 14 |
| 133 | Immunomodulatory and clinical effects of daratumumab in Tâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 191, e28-e32. | 2.5 | 13 |
| 134 | Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 713-719. | 0.4 | 9 |
| 135 | Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematology,the, 2020, 7, e601-e612. | 4.6 | 56 |
| 136 | Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. Blood Advances, 2020, 4, 3239-3245. | 5.2 | 19 |
| 137 | Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e523-e533. | 4.6 | 43 |
| 138 | Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer Journal, 2020, 10, 77. | 6.2 | 65 |
| 139 | Toward a cure in relapsed ALL: we must do better. Leukemia and Lymphoma, 2020, 61, 2544-2545. | 1.3 | 0 |
| 140 | Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement. Seminars in Hematology, 2020, 57, 142-148. | 3.4 | 20 |
| 141 | Who Should Receive an Allogeneic Transplant in First Complete Remission?. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S48-S51. | 0.4 | 0 |
| 142 | Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Annals of Hematology, 2020, 99, 2215-2229. | 1.8 | 29 |
| 143 | Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges. Paediatric Drugs, 2020, 22, 485-499. | 3.1 | 21 |
| 145 | New Approaches to Treating Challenging Subtypes of ALL in AYA Patients. Current Hematologic Malignancy Reports, 2020, 15, 424-435. | 2.3 | 3 |
| 146 | Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?. Frontiers in Oncology, 2020, 10, 608916. | 2.8 | 13 |
| 147 | Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseasesâ€"Implications for Therapeutic Approaches. Cells, 2020, 9, 2627. | 4.1 | 24 |
| 148 | Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020. Seminars in Hematology, 2020, 57, 102-114. | 3.4 | 6 |
| 149 | Recent Advances in Managing Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 330-342. | 3.8 | 40 |
| 150 | How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation. Blood, 2020, 135, 1639-1649. | 1.4 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 151 | The BiTE (bispecific Tâ€cell engager) platform: Development and future potential of a targeted immunoâ€oncology therapy across tumor types. Cancer, 2020, 126, 3192-3201. | 4.1 | 116 |
| 152 | Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Advances, 2020, 4, 2308-2316. | 5.2 | 29 |
| 153 | Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e275-e291. | 3.8 | 32 |
| 154 | Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene. Expert Review of Anticancer Therapy, 2020, 20, 453-464. | 2.4 | 7 |
| 155 | Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab. Therapeutic Advances in Hematology, 2020, 11, 204062072091963. | 2.5 | 4 |
| 156 | Immunotherapy in Hematologic Malignancies. Current Oncology, 2020, 27, 124-131. | 2.2 | 20 |
| 157 | Using Pharmacology to Squeeze the Life Out of Childhood Leukemia, and Potential Strategies to Achieve Breakthroughs in Medulloblastoma Treatment. Pharmacological Reviews, 2020, 72, 668-691. | 16.0 | 6 |
| 158 | IConMHC: a deep learning convolutional neural network model to predict peptide and MHC-I binding affinity. Immunogenetics, 2020, 72, 295-304. | 2.4 | 4 |
| 159 | Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e724-e733. | 0.4 | 7 |
| 160 | Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. Expert Opinion on Biological Therapy, 2021, 21, 831-839. | 3.1 | 9 |
| 161 | Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2020, 11, 204062072092757. | 2.5 | 13 |
| 162 | Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Leukemia and Lymphoma, 2020, 61, 2103-2112. | 1.3 | 55 |
| 163 | Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. Journal of Hematology and Oncology, 2020, 13, 70. | 17.0 | 100 |
| 164 | Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2020, 11, 204062072091002. | 2.5 | 25 |
| 165 | The Many Facets of CD38 in Lymphoma: From Tumorâ€“Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy. Cells, 2020, 9, 802. | 4.1 | 23 |
| 166 | T cell-engaging therapies â€” BiTEs and beyond. Nature Reviews Clinical Oncology, 2020, 17, 418-434. | 27.6 | 296 |
| 167 | Recent Advances in the Management of Acute Lymphoblastic Leukaemia. Current Treatment Options in Oncology, 2020, 21, 23. | 3.0 | 16 |
| 168 | Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Pharmaceuticals, 2020, 13, 124. | 3.8 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 169 | Advances in Supportive Care for Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2020, 15, 276-293. | 2.3 | 8 |
| 170 | Acute lymphoblastic leukemia: From aminopterin to CAR T cells. Medicina ClÃnica (English Edition), 2020, 154, 269-274. | 0.2 | 1 |
| 171 | Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2665-2673. | 1.3 | 44 |
| 172 | Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease. Oncologist, 2020, 25, e709-e715. | 3.7 | 11 |
| 173 | Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, 1084-1090. | 2.0 | 19 |
| 174 | Toxicities of novel therapies for hematologic malignancies. Expert Review of Hematology, 2020, 13, 241-257. | 2.2 | 2 |
| 175 | Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy. Leukemia, 2020, 34, 3064-3069. | 7.2 | 33 |
| 176 | Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics. Journal of Immunotoxicology, 2020, 17, 67-85. | 1.7 | 30 |
| 177 | Harnessing immunotherapy for pediatric T-cell malignancies. Expert Review of Clinical Immunology, 2020, 16, 361-371. | 3.0 | 12 |
| 178 | Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. Cancer, 2020, 126, 1837-1855. | 4.1 | 20 |
| 179 | Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population. Therapeutic Advances in Hematology, 2020, 11, 204062072090353. | 2.5 | 23 |
| 180 | Safety and efficacy of blinatumomab: a real world data. Annals of Hematology, 2020, 99, 835-838. | 1.8 | 19 |
| 181 | Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond. Children, 2020, 7, 14. | 1.5 | 13 |
| 182 | <p>Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy</p>. Biologics: Targets and Therapy, 2020, Volume 14, 23-34. | 3.2 | 23 |
| 183 | A pediatric regimen for adolescents and young adults with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. Cancer Medicine, 2020, 9, 2317-2329. | 2.8 | 13 |
| 184 | Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. Therapeutic Advances in Hematology, 2020, 11, 204062071989989. | 2.5 | 31 |
| 185 | Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia. Bone Marrow Transplantation, 2020, 55, 1410-1420. | 2.4 | 7 |
| 186 | Top 10 Challenges in Cancer Immunotherapy. Immunity, 2020, 52, 17-35. | 14.3 | 1,177 |

| # | Article | IF | Citations |
|---|---|---|---|
| 187 | Treatment of Frail Older Adults and Elderly Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia: Results of a Prospective Trial With Minimal Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e513-e522. | 0.4 | 5 |
| 188 | Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy. Current Hematologic Malignancy Reports, 2020, 15, 187-193. | 2.3 | 1 |
| 189 | Characteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e320-e327. | 0.4 | 5 |
| 190 | Blinatumomab for infant acute lymphoblastic leukemia. Blood, 2020, 135, 1501-1504. | 1.4 | 43 |
| 191 | Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 556-560.e2. | 0.4 | 12 |
| 192 | Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events. Cancer Research, 2020, 80, 91-101. | 0.9 | 54 |
| 193 | How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. Blood, 2020, 135, 804-813. | 1.4 | 34 |
| 194 | Treating Leukemia in the Time of COVID-19. Acta Haematologica, 2021, 144, 132-145. | 1.4 | 57 |
| 195 | Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab. Journal of Oncology Pharmacy Practice, 2021, 27, 821-826. | 0.9 | 7 |
| 196 | Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies. Leukemia and Lymphoma, 2021, 62, 8-31. | 1.3 | 4 |
| 197 | Blinatumomabâ€‰+â€‰ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Leukemia and Lymphoma, 2021, 62, 620-629. | 1.3 | 36 |
| 198 | Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosomeâ€“negative adult lymphoblastic leukemia. Blood, 2021, 137, 1879-1894. | 1.4 | 48 |
| 199 | International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30. | 7.2 | 69 |
| 200 | Acute Leukemias. Hematologic Malignancies, 2021, , . | 0.2 | 2 |
| 201 | Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia. Translational Oncology, 2021, 14, 100978. | 3.7 | 6 |
| 202 | AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 1526-1537. | 7.0 | 86 |
| 203 | Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase <scp>II</scp> pediatricâ€like <scp>GIMEMA LAL</scp>â€1308 trial. American Journal of Hematology, 2021, 96, 292-301. | 4.1 | 21 |
| 204 | Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 1047-1055. | 2.4 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 205 | The management of hematologic malignancies during the COVID-19 pandemic. Expert Opinion on Pharmacotherapy, 2021, 22, 565-582. | 1.8 | 9 |
| 206 | Role of immunoglobulin and antibodies in disease management. International Journal of Biological Macromolecules, 2021, 169, 28-38. | 7.5 | 41 |
| 207 | Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Annals of Oncology, 2021, 32, 34-48. | 1.2 | 231 |
| 208 | Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory Bâ€acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e28718. | 1.5 | 30 |
| 209 | Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood, 2021, 137, 471-484. | 1.4 | 70 |
| 210 | Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for preâ€transplant minimal residual disease reduction. Pediatric Blood and Cancer, 2021, 68, e28574. | 1.5 | 2 |
| 211 | Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL. Blood, 2021, 137, 939-944. | 1.4 | 22 |
| 212 | Liquid biopsy enters the clinic â€" implementation issues and future challenges. Nature Reviews Clinical Oncology, 2021, 18, 297-312. | 27.6 | 609 |
| 213 | Acute Lymphoblastic Leukemia. , 2021, , 251-270. | | 0 |
| 214 | Early autologous and allogeneic peripheral blood stem cell transplantation for adult patients with acute B and T cell precursor neoplasms: a 12-year single center experience. Annals of Hematology, 2021, 100, 809-816. | 1.8 | 2 |
| 215 | Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries. MAbs, 2021, 13, 1859049. | 5.2 | 5 |
| 216 | Overcoming the challenges associated with CD3+ T-cell redirection in cancer. British Journal of Cancer, 2021, 124, 1037-1048. | 6.4 | 42 |
| 217 | Therapeutic Approaches to Employ Monoclonal Antibody for Cancer Treatment. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 42-88. | 0.1 | 0 |
| 218 | CAR T cells better than BiTEs. Blood Advances, 2021, 5, 602-606. | 5.2 | 17 |
| 219 | Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. Blood Reviews, 2021, 45, 100709. | 5.7 | 24 |
| 220 | BiTEs better than CAR T cells. Blood Advances, 2021, 5, 607-612. | 5.2 | 59 |
| 221 | Immunophenotypic Profile of Blast Cells as a Marker for Diagnosis of Relapsed Children Acute Lymphoblastic Leukemia. UkraÃ¯nsÊ¹kij Å¾urnal Medicini BÅ¬ologÃ¬Ã¯ Ta Sportu, 2021, 6, 56-64. | 0.2 | 0 |
| 222 | DARTs point the way forward in AML. Blood, 2021, 137, 720-721. | 1.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 223 | The impact of phenotypic heterogeneity of tumour cells on treatment and relapse dynamics. PLoS Computational Biology, 2021, 17, e1008702. | 3.2 | 11 |
| 224 | Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplantÂmeasurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. Leukemia, 2021, 35, 2232-2242. | 7.2 | 6 |
| 225 | Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. , 2021, 9, e002026. | | 11 |
| 226 | Minimal Residual Disease in Acute Lymphoblastic Leukemia. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 071-076. | 0.2 | 1 |
| 227 | Blinatumomab-induced T cell activation at single cell transcriptome resolution. BMC Genomics, 2021, 22, 145. | 2.8 | 11 |
| 228 | Cytokine gene polymorphisms are associated with response to blinatumomab in Bâ€cell acute lymphoblastic leukemia. European Journal of Haematology, 2021, 106, 851-858. | 2.2 | 2 |
| 229 | Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells. Experimental Hematology, 2021, 95, 31-45. | 0.4 | 15 |
| 230 | Have any strategies in Ph-like ALL been shown to be effective?. Best Practice and Research in Clinical Haematology, 2021, 34, 101242. | 1.7 | 10 |
| 231 | T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs). Anticancer Research, 2021, 41, 1123-1141. | 1.1 | 6 |
| 232 | Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2021, 325, 830. | 7.4 | 11 |
| 233 | Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2021, 325, 843. | 7.4 | 166 |
| 234 | Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory Bâ€cell precursor acute lymphoblastic leukemia: Results of a pooled analysis. Cancer Medicine, 2021, 10, 2601-2610. | 2.8 | 8 |
| 235 | Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2021, 325, 833. | 7.4 | 177 |
| 236 | Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports. Journal of Medical Case Reports, 2021, 15, 164. | 0.8 | 4 |
| 237 | PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology, 2021, 11, 642466. | 2.8 | 14 |
| 238 | Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory bâ€precursor acute lymphoblastic leukaemia: Case reports and literature review. Pediatric Blood and Cancer, 2021, 68, e29044. | 1.5 | 7 |
| 239 | Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment. Expert Review of Precision Medicine and Drug Development, 2021, 6, 203-215. | 0.7 | 2 |
| 240 | Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Medicine, 2021, 10, 1926. | 2.4 | 86 |

| # | Article | IF | Citations |
|---|---|---|---|
| 241 | Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e365-e372. | 0.4 | 3 |
| 242 | Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency. Blood Advances, 2021, 5, 2153-2155. | 5.2 | 8 |
| 243 | CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease. Cancer Immunology, Immunotherapy, 2021, 70, 3501-3511. | 4.2 | 12 |
| 244 | Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplantation, 2021, 56, 1998-2004. | 2.4 | 11 |
| 245 | Has MRD graduated from its adolescence in ALL?. Blood, 2021, 137, 1846-1847. | 1.4 | 0 |
| 246 | MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL. Cancers, 2021, 13, 2108. | 3.7 | 5 |
| 247 | Development of a bispecific immune engager using a recombinant malaria protein. Cell Death and Disease, 2021, 12, 353. | 6.3 | 5 |
| 248 | Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. Cancers, 2021, 13, 2712. | 3.7 | 13 |
| 249 | T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia, 2021, 35, 1843-1863. | 7.2 | 123 |
| 250 | Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT. Leukemia Research, 2021, 104, 106579. | 0.8 | 4 |
| 251 | The use of intrathecal chemotherapy and dexamethasone for secondary prevention of blinatumomab-related neurotoxicity. Current Research in Translational Medicine, 2021, 69, 103285. | 1.8 | 7 |
| 252 | Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circulation Research, 2021, 128, 1780-1801. | 4.5 | 48 |
| 253 | Relationship of genetic deviations with laboratory indicators of peripheral blood and bone marrow in children with acute lymphoblastic leukemia. Bukovinian Medical Herald, 2021, 25, 11-18. | 0.1 | 0 |
| 254 | Bispecific Antibodies: From Research to Clinical Application. Frontiers in Immunology, 2021, 12, 626616. | 4.8 | 129 |
| 255 | The landscape of bispecific T cell engager in cancer treatment. Biomarker Research, 2021, 9, 38. | 6.8 | 90 |
| 256 | Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. Journal of Hematology and Oncology, 2021, 14, 75. | 17.0 | 107 |
| 257 | Expanding the Toolbox of Adoptive Cell Immunotherapy. Journal of Clinical Oncology, 2021, 39, 1479-1482. | 1.6 | 0 |
| 258 | BiTEs, DARTS, BiKEs and TriKEsâ€"Are Antibody Based Therapies Changing the Future Treatment of AML?. Life, 2021, 11, 465. | 2.4 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 259 | The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. Frontiers in Immunology, 2021, 12, 670286. | 4.8 | 16 |
| 260 | Efficacy and tolerability of a modified pediatricâ€inspired intensive regimen for acute lymphoblastic leukemia in older adults. EJHaem, 2021, 2, 413-420. | 1.0 | 4 |
| 261 | Relapsed Babesia microti Infection Following Allogeneic Hematopoietic Cell Transplantation in a Patient With B-cell Acute Lymphoblastic Leukemia: Case Report and Review of the Literature. Open Forum Infectious Diseases, 2021, 8, ofab323. | 0.9 | 6 |
| 262 | Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia. Scientific Reports, 2021, 11, 13158. | 3.3 | 10 |
| 263 | T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia. Cancers, 2021, 13, 3255. | 3.7 | 6 |
| 264 | Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia, 2021, 35, 3044-3058. | 7.2 | 29 |
| 265 | Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia. Expert Opinion on Investigational Drugs, 2021, 30, 773-784. | 4.1 | 8 |
| 266 | Targeted Therapy in Acute Lymphoblastic Leukaemia. Journal of Personalized Medicine, 2021, 11, 715. | 2.5 | 8 |
| 267 | Modified Therapeutic Antibodies: Improving Efficacy. Engineering, 2021, 7, 1529-1540. | 6.7 | 3 |
| 268 | Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 686031. | 4.8 | 19 |
| 269 | Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia. Expert Review of Hematology, 2021, 14, 765-775. | 2.2 | 8 |
| 270 | The Care of the Leukemic Patients in Times of SARS-CoV-2. Current Oncology Reports, 2021, 23, 114. | 4.0 | 2 |
| 271 | Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase. JCO Precision Oncology, 2021, 5, 1141-1146. | 3.0 | 6 |
| 272 | Trials and Tribulations in the Frontline Treatment of Older Adults with Acute Myeloid Leukemia. Hemato, 2021, 2, 515-544. | 0.6 | 0 |
| 273 | Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults. Leukemia and Lymphoma, 2021, 62, 3333-3347. | 1.3 | 2 |
| 274 | Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?. Hematology/Oncology Clinics of North America, 2021, 35, 775-791. | 2.2 | 8 |
| 275 | Strong expansion of normal CD19â€negative Bâ€cell precursors after the use of blinatumomab in the firstâ€line therapy of acute lymphoblastic leukaemia in children. British Journal of Haematology, 2022, 196, . | 2.5 | 6 |
| 276 | Refractory DLBCL: Challenges and Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 140-148. | 0.4 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 277 | The promise of bispecific antibodies: Clinical applications and challenges. Cancer Treatment Reviews, 2021, 99, 102240. | 7.7 | 28 |
| 278 | Optimal Timing of Blinatumomab for the Treatment of B-Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S99-S101. | 0.4 | 0 |
| 279 | Novel Transplant and Post-Transplant Options in ALL. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S7-S9. | 0.4 | 0 |
| 280 | The promise and perils of immunotherapy. Blood Advances, 2021, 5, 3709-3725. | 5.2 | 23 |
| 281 | Bispecific antibodies for non-Hodgkinâ€™s lymphomas and multiple myeloma. Drugs in Context, 2021, 10, 1-12. | 2.2 | 6 |
| 282 | Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1079-1109. | 4.9 | 96 |
| 283 | Different Kinetics and Risk Factors for Isolated Extramedullary Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Leukemia. Transplantation and Cellular Therapy, 2021, 27, 859.e1-859.e10. | 1.2 | 4 |
| 284 | A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions. Annals of Pharmacotherapy, 2021, 55, 1236-1253. | 1.9 | 6 |
| 285 | Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. Molecular Cancer, 2021, 20, 5. | 19.2 | 12 |
| 287 | Blinatumomab in pediatric patients with relapsed/refractory Bâ€cell precursor acute lymphoblastic leukemia. European Journal of Haematology, 2021, 106, 473-483. | 2.2 | 38 |
| 288 | Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2020, 15, 294-304. | 2.3 | 17 |
| 289 | Investigation of the effect of salt additives in Protein L affinity chromatography for the purification of tandem single-chain variable fragment bispecific antibodies. MAbs, 2020, 12, 1718440. | 5.2 | 23 |
| 290 | Navigating the nexus of MRD and novel agents in ALL. Hematology American Society of Hematology Education Program, 2019, 2019, 9-16. | 2.5 | 2 |
| 291 | Moving immunotherapy into the front line in ALL. Hematology American Society of Hematology Education Program, 2019, 2019, 209-217. | 2.5 | 13 |
| 292 | Philadelphia Chromosomeâ€“Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. JCO Oncology Practice, 2020, 16, 231-238. | 2.9 | 4 |
| 293 | New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. Minerva Medica, 2020, 111, 478-490. | 0.9 | 4 |
| 294 | Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies. Clinical Hematology International, 2019, 1, 79. | 1.7 | 15 |
| 295 | Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia. Clinical Hematology International, 2019, 1, 85-93. | 1.7 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 296 | Pediatric acute lymphoblastic leukemia. Haematologica, 2020, 105, 2524-2539. | 3.5 | 313 |
| 297 | Why Immunotherapy Fails in Multiple Myeloma. Hemato, 2021, 2, 1-42. | 0.6 | 5 |
| 298 | Blood and Bone Marrow Transplantation in India: Past, Present, and Future. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 308-311. | 0.2 | 8 |
| 299 | Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 414-423. | 4.9 | 44 |
| 300 | Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 81-112. | 4.9 | 102 |
| 301 | Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia. Drugs in Context, 2020, 9, 1-15. | 2.2 | 5 |
| 302 | Integrative transcriptome data mining for identification of core lncRNAs in breast cancer. PeerJ, 2019, 7, e7821. | 2.0 | 30 |
| 303 | Current and Emerging Therapies for Acute Myeloid Leukemia. Cancer Treatment and Research, 2021, 181, 57-73. | 0.5 | 2 |
| 304 | An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. Blood Advances, 2021, 5, 5574-5583. | 5.2 | 6 |
| 305 | The cure of leukemia through the optimist's prism. Cancer, 2022, 128, 240-259. | 4.1 | 17 |
| 306 | Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?. Best Practice and Research in Clinical Haematology, 2021, 34, 101331. | 1.7 | 6 |
| 307 | Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer, 2022, 128, 529-535. | 4.1 | 17 |
| 308 | Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. Current Problems in Cancer, 2021, 45, 100794. | 2.0 | 4 |
| 309 | Application of Next-Generation Sequencing-Based Mutational Profiling in Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports, 2021, 16, 394-404. | 2.3 | 2 |
| 310 | Next-Generation Sequencing for Measurable Residual Disease Assessment in Acute Leukemia. Advances in Molecular Pathology, 2021, 4, 49-63. | 0.4 | 2 |
| 311 | Game changers in pediatric cancer. Journal of Community and Supportive Oncology, 2018, 16, e210-e216. | 0.1 | 0 |
| 312 | Resistance to Bispecific T-Cell Engagers and Bispecific Antibodies. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 181-192. | 0.1 | 2 |
| 313 | Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Russian Multicenter Clinical Trial. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2019, 12, 45-53. | 0.4 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 314 | El trasplante alogÃ©nico de progenitores hematopoyÃ©ticos en la era de las nuevas terapias en la leucemia linfoblÃ¡stica aguda. Medicina ClÃnica, 2019, 153, 28-34. | 0.6 | 2 |
| 315 | Clinical Experience with Bispecific T Cell Engagers. Recent Results in Cancer Research, 2020, 214, 71-91. | 1.8 | 2 |
| 316 | Adolescents and Young Adults with Acute Lymphoblastic Leukemia. , 2020, , 109-122. | | 0 |
| 317 | Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1448-1450. | 4.9 | 0 |
| 318 | Opportunities for immunotherapy in childhood acute myeloid leukemia. Hematology American Society of Hematology Education Program, 2019, 2019, 218-225. | 2.5 | 1 |
| 320 | Immunotherapy for Hematological Malignancies â€“ Now and Future â€“.. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 301-307. | 0.0 | 0 |
| 321 | Leucemia aguda linfoblÃ¡stica: de la aminopterina a las cÃ©lulas CAR T. Medicina ClÃnica, 2020, 154, 269-274. | 0.6 | 1 |
| 322 | Will immunotherapy lead to a breakthrough in the treatment of older adults with ALL?. Best Practice and Research in Clinical Haematology, 2021, 34, 101319. | 1.7 | 1 |
| 323 | Detection of measurable residual disease in adults with acute leukaemia. Gematologiya I Transfuziologiya, 2020, 65, 460-472. | 0.6 | 4 |
| 324 | Neue Arzneimittel 2019. , 2020, , 43-150. | | 2 |
| 325 | Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48. | | 0 |
| 326 | Treatment of Acute Lymphoid Leukemia Refractory to Classic First-Line and Rescue Protocols. International Journal of Hematology-Oncology and Stem Cell Research, 0, , . | 0.3 | 0 |
| 327 | Immunotherapy in Pediatric Hematologic Malignant Neoplasms. Clinical Pediatric Hematology-Oncology, 2020, 27, 14-21. | 0.2 | 0 |
| 328 | New approaches to the treatment of older adults with acute lymphoblastic leukemia. Seminars in Hematology, 2020, 57, 122-129. | 3.4 | 3 |
| 329 | Hematopoietic Cell Transplantation (HCT) for Acute Lymphoblastic Leukemia (ALL). Hematologic Malignancies, 2021, , 193-204. | 0.2 | 0 |
| 330 | Minimal or Measurable Residual Disease in Acute Lymphoblastic Leukemia. Hematologic Malignancies, 2021, , 205-218. | 0.2 | 0 |
| 332 | Management of Relapsed and Refractory ALL. Hematologic Malignancies, 2021, , 277-289. | 0.2 | 0 |
| 333 | Immuno-Target Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia. Korean Journal of Medicine, 2020, 95, 320-324. | 0.3 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 335 | To Transplant or Not? Weighing the Risks of Blinatumomab Prior to Hematopoietic Stem Cell Transplant in Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, e209-e210. | 2.0 | 0 |
| 336 | Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications. American Journal of Blood Research, 2018, 8, 29-56. | 0.6 | 21 |
| 337 | Treatment of Acute Lymphoid Leukemia Refractory to Classic First-Line and Rescue Protocols. International Journal of Hematology-Oncology and Stem Cell Research, 2020, 14, 123-126. | 0.3 | 0 |
| 338 | Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60Âyears of progress in the treatment of adult ALL. British Journal of Haematology, 2020, 191, 558-561. | 2.5 | 1 |
| 340 | How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia. Clinical Hematology International, 2021, 3, 130. | 1.7 | 6 |
| 341 | BiTEs Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 342 | Immuntherapie. , 2022, , 53-58. | | 0 |
| 343 | Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Cancers, 2021, 13, 5607. | 3.7 | 3 |
| 344 | T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. Pharmaceuticals, 2021, 14, 1172. | 3.8 | 13 |
| 346 | Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Frontiers in Oncology, 2021, 11, 804714. | 2.8 | 9 |
| 350 | Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a realâ€world setting: Results from the NEUF study. Pediatric Blood and Cancer, 2022, 69, e29562. | 1.5 | 8 |
| 351 | The Next Wave of Novel Agents in Aggressive B-Cell Lymphoma: Highlights From SOHO 2021. Journal of the Advanced Practitioner in Oncology, 2022, 13, 34-36. | 0.4 | 0 |
| 352 | Haematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukaemia: Special Considerations and Challenges. Frontiers in Pediatrics, 2021, 9, 796426. | 1.9 | 4 |
| 353 | Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy. Oncologist, 2022, 27, 82-86. | 3.7 | 5 |
| 354 | The treatment landscape for Relapsed Refractory B Acute Lymphoblastic Leukaemia (ALL). Leukemia and Lymphoma, 2022, , 1-10. | 1.3 | 0 |
| 356 | Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia. Cancers, 2022, 14, 458. | 3.7 | 10 |
| 357 | Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 | | |
| 358 | Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. Blood Advances, 2022, 6, 1004-1014. | 5.2 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 359 | Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia. Cancer Immunology Research, 2022, 10, 291-302. | 3.4 | 17 |
| 360 | From Myth to Reality: Achieving a Second Remission in Acute Lymphoblastic Leukemia. , 2022, 19, . | | 0 |
| 363 | Monoclonal Antibody-Based Treatment and Other New Agents for B-Lineage Acute Lymphoblastic Leukemia. , 2022, , 295-328. | | 2 |
| 364 | A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells <i>in vitro</i> and <i>in vivo</i>. Haematologica, 2022, 107, 1786-1795. | 3.5 | 5 |
| 365 | Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia, 2022, 36, 1253-1260. | 7.2 | 9 |
| 366 | Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60Âyears of progress in the treatment of adult ALL. British Journal of Haematology, 2020, 191, 558-561. | 2.5 | 2 |
| 367 | Bispecific Antibodies for the Treatment of Neuroblastoma. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 368 | Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia Research Reports, 2022, 17, 100294. | 0.4 | 1 |
| 369 | Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody. Immune Network, 2022, 22, e4. | 3.6 | 12 |
| 370 | SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosomeâ€"Negative B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2022, 40, 1574-1582. | 1.6 | 44 |
| 372 | Empathetic nursing with mindful cognitive therapy for fatigue, depression, and negative emotions in leukemia patients undergoing long-term chemotherapy. World Journal of Clinical Cases, 2022, 10, 1826-1833. | 0.8 | 1 |
| 373 | Dismal outcomes of patients with relapsed/refractory Philadelphia chromosomeâ€negative Bâ€cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. American Journal of Hematology, 2022, 97, . | 4.1 | 7 |
| 374 | Impact of Circulating Tumor DNAâ€"Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO Precision Oncology, 2022, 6, e2100181. | 3.0 | 33 |
| 375 | Very rare nearâ€haploid acute lymphoblastic leukemia resistant to immunotherapy and CARâ€T therapy in 19â€yearâ€old male patient. Clinical Case Reports (discontinued), 2022, 10, e05545. | 0.5 | 2 |
| 376 | Resistance Mechanisms in Pediatric B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 2022, 23, 3067. | 4.1 | 6 |
| 377 | Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic. Genes and Development, 2022, 36, 259-277. | 5.9 | 19 |
| 378 | SOHO State of the Art Updates and Next Questions: Novel Transplant and Post-Transplant Options in Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2022, , . | 0.4 | 0 |
| 379 | Controversies in the Treatment of Adolescents and Young Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Current Oncology Reports, 2022, , 1. | 4.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 380 | Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia. Blood and Lymphatic Cancer: Targets and Therapy, 2022, Volume 12, 7-16. | 2.7 | 9 |
| 381 | Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells. Human Gene Therapy, 2022, 33, 649-663. | 2.7 | 5 |
| 382 | Immunotherapies in acute leukemia. Therapie, 2022, 77, 241-250. | 1.0 | 3 |
| 383 | Anticancer effects of a single intramuscular dose of a minicircle DNA vector expressing anti-CD3/CD20 in a xenograft mouse model. Molecular Therapy - Oncolytics, 2022, 24, 788-798. | 4.4 | 3 |
| 384 | High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL.. Haematologica, 2022, , . | 3.5 | 10 |
| 385 | Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults. Cancers, 2022, 14, 1805. | 3.7 | 10 |
| 386 | In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial. Lancet Haematology,the, 2022, 9, e276-e288. | 4.6 | 12 |
| 387 | Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!. JCO Oncology Practice, 2022, 18, 479-487. | 2.9 | 17 |
| 388 | Liquid biopsies for residual disease and recurrence. Med, 2021, 2, 1292-1313. | 4.4 | 15 |
| 389 | Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy. Annual Review of Cancer Biology, 2022, 6, 17-34. | 4.5 | 23 |
| 390 | MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?. Hematology American Society of Hematology Education Program, 2021, 2021, 718-725. | 2.5 | 6 |
| 391 | Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?. Hematology American Society of Hematology Education Program, 2021, 2021, 7-14. | 2.5 | 5 |
| 392 | SOHO State of the Art Updates and Next Questions: Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future. Clinical Lymphoma, Myeloma and Leukemia, 2021, , . | 0.4 | 1 |
| 395 | Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies. Cancer Treatment and Research, 2022, 183, 287-315. | 0.5 | 0 |
| 396 | A Chemotherapy-free Regimen for Older Adults and Relapsed or Refractory B-ALL. , 2022, 19, . | | 2 |
| 397 | Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric highâ€risk first relapse Bâ€cell precursor acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2022, 69, e29715. | 1.5 | 10 |
| 398 | Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e836-e843. | 0.4 | 1 |
| 399 | Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies. Pharmaceutics, 2022, 14, 970. | 4.5 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 400 | Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 584-594. | 3.8 | 2 |
| 401 | Targeting Apoptosis in ALL. Current Hematologic Malignancy Reports, 2022, , 1. | 2.3 | 2 |
| 403 | Monoclonal antibodies in frontline therapy of adult acute lymphoblastic leukemia: A step ahead. Medicina ClÃnica (English Edition), 2022, 158, 476-476. | 0.2 | 0 |
| 404 | High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Advances, 2022, 6, 4006-4014. | 5.2 | 37 |
| 405 | <scp>VANDA</scp> regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosomeâ€negative Bâ€precursor acute lymphoblastic leukaemia in first relapse. British Journal of Haematology, 2022, , . | 2.5 | 2 |
| 407 | Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence?. Clinical Hematology International, 0, , 1. | 1.7 | 3 |
| 408 | BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2759-2771. | 2.5 | 2 |
| 409 | Therapeutic bispecific antibodies against intracellular tumor antigens. Cancer Letters, 2022, 538, 215699. | 7.2 | 12 |
| 410 | Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy, 2022, , . | 1.2 | 3 |
| 411 | Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy. Blood and Lymphatic Cancer: Targets and Therapy, 0, Volume 12, 55-79. | 2.7 | 14 |
| 412 | The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 2022, 6, e726. | 2.7 | 1 |
| 413 | MRD in ALL: Optimization and Innovations. Current Hematologic Malignancy Reports, 2022, 17, 69-81. | 2.3 | 6 |
| 414 | Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology, 2022, 27, 642-652. | 1.5 | 11 |
| 415 | New Therapeutic Strategies for Adult Acute Myeloid Leukemia. Cancers, 2022, 14, 2806. | 3.7 | 15 |
| 416 | Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2022, 386, 2399-2411. | 27.0 | 31 |
| 417 | The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations. Expert Review of Anticancer Therapy, 2022, 22, 845-860. | 2.4 | 2 |
| 418 | The current state of molecular profiling in gastrointestinal malignancies. Biology Direct, 2022, 17, . | 4.6 | 5 |
| 419 | Blinatumomab is associated with favorable outcomes in patients with Bâ€cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10<sup>â^'4</sup> and higher. American Journal of Hematology, 2022, 97, 1135-1141. | 4.1 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 420 | Comment on: Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric highâ€risk first relapse Bâ€cell precursor acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2023, 70, . | 1.5 | 0 |
| 421 | Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. Leukemia Research, 2022, 119, 106885. | 0.8 | 2 |
| 422 | Use of Circulating Tumour DNA to Assess Minimal Residual Disease in Gastrointestinal Cancers. Touch Reviews in Oncology & Haematology, 2022, 18, 26. | 0.2 | 0 |
| 423 | Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics. Science Advances, 2022, 8, . | 10.3 | 7 |
| 424 | Bispecific antibodies for the treatment of neuroblastoma. , 2022, 237, 108241. | | 3 |
| 425 | Antibody variable region engineering for improving cancer immunotherapy. Cancer Communications, 2022, 42, 804-827. | 9.2 | 15 |
| 426 | Excellent removal of knob-into-hole bispecific antibody byproducts and impurities in a single-capture chromatography. Bioresources and Bioprocessing, 2022, 9, . | 4.2 | 5 |
| 427 | The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis. Frontiers in Pediatrics, 0, 10, . | 1.9 | 14 |
| 429 | The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. Journal of Clinical Pharmacy and Therapeutics, 0, , . | 1.5 | 4 |
| 430 | Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study. Hematology, 2022, 27, 917-927. | 1.5 | 3 |
| 431 | A phase two study of high dose blinatumomab in Richterâ€™s syndrome. Leukemia, 2022, 36, 2228-2232. | 7.2 | 10 |
| 432 | Bispecific Antibodies for the Treatment of Multiple Myeloma. Current Hematologic Malignancy Reports, 2022, 17, 286-297. | 2.3 | 4 |
| 433 | Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation. Leukemia Research, 2022, 121, 106930. | 0.8 | 3 |
| 434 | Top advances of the year: Pediatric oncology. Cancer, 2022, 128, 3593-3596. | 4.1 | 0 |
| 435 | Effective flow-through polishing strategies for knob-into-hole bispecific antibodies. Bioresources and Bioprocessing, 2022, 9, . | 4.2 | 3 |
| 436 | EXABS-136-ALL Certain Patients with ALL Still Need a Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, S47-S49. | 0.4 | 0 |
| 437 | EXABS-132-ALL Approach to Acute Lymphoblastic Leukemia in The Elderly. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, S34-S38. | 0.4 | 0 |
| 438 | Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies. Current Opinion in Biotechnology, 2022, 78, 102799. | 6.6 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 439 | Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy, 2022, , . | 1.2 | 5 |
| 440 | Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective. Expert Review of Hematology, 2022, 15, 789-803. | 2.2 | 3 |
| 441 | Case Analysis in Drug Approval by FDA/EMA Using Real-World Data/Real-World Evidence. , 2022, 14, 133-143. | | 0 |
| 442 | Targeted Treatment and Immunotherapy in High-risk and Relapsed/ Refractory Pediatric Acute Lymphoblastic Leukemia. Current Pediatric Reviews, 2023, 19, 150-156. | 0.8 | 1 |
| 443 | A Probody T Cellâ€"Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity. Cancer Research, 2022, 82, 4288-4298. | 0.9 | 13 |
| 445 | Therapeutic Advances in Immunotherapies for Hematological Malignancies. International Journal of Molecular Sciences, 2022, 23, 11526. | 4.1 | 6 |
| 446 | Hyper-CVAD-Based Stem Cell Microtransplant as Post-Remission Therapy in Acute Lymphoblastic Leukemia. Stem Cells Translational Medicine, 2022, 11, 1113-1122. | 3.3 | 1 |
| 447 | Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia. Lancet Haematology,the, 2022, 9, e864-e865. | 4.6 | 1 |
| 448 | Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematology,the, 2022, 9, e878-e885. | 4.6 | 23 |
| 449 | Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia, 2022, 36, 2817-2826. | 7.2 | 14 |
| 451 | Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?. Best Practice and Research in Clinical Haematology, 2022, 35, 101407. | 1.7 | 2 |
| 452 | Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement. Immunological Investigations, 2022, 51, 2176-2214. | 2.0 | 5 |
| 453 | When will chemotherapy be replaced in upfront induction therapy for adult acute lymphoblastic leukemia (ALL)?. Best Practice and Research in Clinical Haematology, 2022, 35, 101404. | 1.7 | 0 |
| 454 | Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Frontiers in Immunology, 0, 13, . | 4.8 | 36 |
| 455 | Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. Blood Advances, 2023, 7, 1279-1285. | 5.2 | 9 |
| 456 | Neurotoxicity with blinatumomab in combination with intrathecal methotrexate therapy. Leukemia and Lymphoma, 0, , 1-4. | 1.3 | 2 |
| 457 | Immunotherapy approaches for hematological cancers. IScience, 2022, 25, 105326. | 4.1 | 9 |
| 458 | Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy. Cancers, 2022, 14, 5445. | 3.7 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 459 | Marker fÃ¼r minimale Resterkrankung: Minimal Residual Disease. Springer Reference Medizin, 2022, , 1-8. | 0.0 | 0 |
| 461 | Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment. International Journal of Molecular Sciences, 2022, 23, 15006. | 4.1 | 4 |
| 462 | Efficacy and Safety of Blinatumomab for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, e139-e149. | 0.4 | 2 |
| 463 | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2022, , . | 0.4 | 0 |
| 464 | Cancer Immunotherapy Beyond Checkpoint Blockade. JACC: CardioOncology, 2022, 4, 563-578. | 4.0 | 1 |
| 465 | Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer Journal, 2022, 12, . | 6.2 | 5 |
| 466 | PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Science Advances, 2022, 8, . | 10.3 | 5 |
| 467 | Central Nervous System Prophylaxis and Treatment in Acute Leukemias. Current Treatment Options in Oncology, 2022, 23, 1829-1844. | 3.0 | 3 |
| 468 | Blinatumomab in Relapsed/Refractory Burkitt Lymphoma. Cancers, 2023, 15, 44. | 3.7 | 2 |
| 469 | Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica, 2022, 107, 2783-2793. | 3.5 | 12 |
| 470 | The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives. Experimental Hematology and Oncology, 2023, 12, . | 5.0 | 7 |
| 471 | Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions. OncoTargets and Therapy, 0, Volume 16, 1-16. | 2.0 | 1 |
| 472 | Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study. Blood Cancer Journal, 2023, 13, . | 6.2 | 3 |
| 473 | Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy. Pharmaceutics, 2023, 15, 132. | 4.5 | 2 |
| 474 | Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Molecular Cell, 2023, 83, 660-680. | 9.7 | 10 |
| 475 | Cellular and Vaccine-Based Immunotherapy for Hematologic Malignancies. , 2023, , . | | 0 |
| 476 | Bispecific Antibodies in Targeted Cancer Immunotherapy. , 2023, , 1-46. | | 1 |
| 477 | Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia. Clinical and Experimental Medicine, 0, , . | 3.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 478 | Sequencing <scp>antigenâ€targeting</scp> antibodies and cellular therapies in adults with relapsed/refractory <scp>Bâ€cell</scp> acute lymphoblastic leukemia. American Journal of Hematology, 2023, 98, 666-680. | 4.1 | 3 |
| 479 | TRYBEÂ®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life. MAbs, 2023, 15, . | 5.2 | 1 |
| 480 | Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL. Cancers, 2023, 15, 1349. | 3.7 | 0 |
| 481 | Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer. Cancers, 2023, 15, 1412. | 3.7 | 5 |
| 482 | Blinatumomab therapy for B cell acute lymphoblastic leukemia accompanied by persistent or relapsed low-level MRD prior to hematopoietic stem cell transplantation in Chinese children: a case series. Bulletin of the National Research Centre, 2023, 47, . | 1.8 | 0 |
| 483 | Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory Bâ€cell acute lymphoblastic leukemia. Cancer, 2023, 129, 1384-1393. | 4.1 | 4 |
| 484 | Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies. Translational Pediatrics, 2023, 12, 487-502. | 1.2 | 2 |
| 485 | The role of blinatumomab in the treatment of B-cell relapses of acute lymphoblastic leukemia in children: own experience. Pediatric Hematology/Oncology and Immunopathology, 2023, 22, 62-72. | 0.3 | 0 |
| 486 | Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. International Journal of Molecular Sciences, 2023, 24, 4790. | 4.1 | 5 |
| 487 | Approach to the Treatment of Philadelphia Chromosome-Negative B-cell ALL in Older Adults: Is Age Becoming just a Number?. Current Hematologic Malignancy Reports, 0, , . | 2.3 | 0 |
| 488 | The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades. Journal of Hematology and Oncology, 2023, 16, . | 17.0 | 18 |
| 489 | Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. JCO Oncology Practice, 0, , . | 2.9 | 0 |
| 490 | Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia. Annals of Hematology, 2023, 102, 1275-1277. | 1.8 | 0 |
| 491 | Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. Lancet Haematology,the, 2023, 10, e382-e388. | 4.6 | 7 |
| 492 | Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet, The, 2023, 401, 1447-1457. | 13.7 | 28 |
| 493 | Immunotherapy for Acute Leukemia. , 2022, , 1-41. | | 0 |
| 494 | Role of measurable residual disease quantified by 4 to 6 color flow cytometry before allogeneic hematopoietic stem cell transplantation for high-risk Philadelphia-negative acute lymphoblastic leukemia. Journal of Stem Cell Therapy and Transplantation, 2023, 7, 016-023. | 0.3 | 0 |
| 495 | Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. New England Journal of Medicine, 2023, 388, 1572-1581. | 27.0 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 496 | Targeting N-cadherin (CDH2) and the malignant bone marrow microenvironment in acute leukaemia. Expert Reviews in Molecular Medicine, 2023, 25, . | 3.9 | 3 |
| 497 | Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission. Leukemia and Lymphoma, 2023, 64, 1285-1294. | 1.3 | 0 |
| 498 | Expert Recommendations for the Diagnosis, Treatment, and Management of Adult B-Cell Acute Lymphoblastic Leukemia in Latin America. JCO Global Oncology, 2023, , . | 1.8 | 1 |
| 499 | Next-generation sequencingâ€"based MRD in adults with ALL undergoing hematopoietic cell transplantation. Blood Advances, 2023, 7, 3395-3402. | 5.2 | 7 |
| 500 | The clinical application of immuno-therapeutics. , 2024, , 237-288.e7. | | 0 |
| 501 | Current applications of biomolecules in biopharmaceuticals and drug discovery. , 2023, , 439-466. | | 0 |
| 502 | Introduction about monoclonal antibodies. , 2023, , 1-38. | | 1 |
| 503 | Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse. Journal of Clinical Oncology, 2023, 41, 4118-4129. | 1.6 | 7 |
| 504 | Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia. Frontiers in Immunology, 0, 14, . | 4.8 | 0 |
| 505 | The expanding success of T cell-engaging bispecific antibodies. Nature Cancer, 2023, 4, 1054-1055. | 13.2 | 3 |
| 506 | Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond. Cancers, 2023, 15, 3346. | 3.7 | 2 |
| 507 | CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months. Blood Cancer Journal, 2023, 13, . | 6.2 | 0 |
| 508 | Ultrasensitive <scp>NGS MRD</scp> assessment in Ph+â€‰<scp>ALL</scp>: Prognostic impact and correlation with <scp>RTâ€PCR</scp> for BCR::ABL1. American Journal of Hematology, 2023, 98, 1196-1203. | 4.1 | 13 |
| 509 | Simultaneous evaluation of treatment efficacy and toxicity for bispecific Tâ€cell engager therapeutics in a humanized mouse model. FASEB Journal, 2023, 37, . | 0.5 | 0 |
| 510 | T-cell-engaging bispecific antibodies in cancer. Lancet, The, 2023, 402, 142-158. | 13.7 | 27 |
| 511 | Harnessing the Immune System: Current and Emerging Immunotherapy Strategies for Pediatric Acute Lymphoblastic Leukemia. Biomedicines, 2023, 11, 1886. | 3.2 | 1 |
| 512 | T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions. Frontiers in Oncology, 0, 13, . | 2.8 | 0 |
| 513 | Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy. Annals of Medicine, 2023, 55, . | 3.8 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 514 | Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. Journal of Hematology and Oncology, 2023, 16, . | 17.0 | 6 |
| 515 | Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy. Experimental Hematology and Oncology, 2023, 12, . | 5.0 | 3 |
| 516 | Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. Journal of Hematology and Oncology, 2023, 16, . | 17.0 | 12 |
| 517 | Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress. Cancers, 2023, 15, 4137. | 3.7 | 2 |
| 518 | Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment. Frontiers in Oncology, 0, 13, . | 2.8 | 1 |
| 519 | EXABS-103-ALL MRD in Ph+ ALL: How Do You Measure It and What Does It Mean?. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, S5-S7. | 0.4 | 0 |
| 520 | Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study. Cancers, 2023, 15, 4623. | 3.7 | 2 |
| 521 | Bispecific Antibodies in Hematological Malignancies: A Scoping Review. Cancers, 2023, 15, 4550. | 3.7 | 2 |
| 522 | All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia. Hematology, Transfusion and Cell Therapy, 2023, , . | 0.2 | 0 |
| 523 | New monoclonal antibodies for the treatment of acute lymphoblastic leukemia. , 2024, , 165-192. | | 0 |
| 524 | Hematopoietic cell transplantation landscape in India. Medical Journal Armed Forces India, 2023, , . | 0.8 | 0 |
| 525 | In the Pipelineâ€"Emerging Therapy for ALL. , 2023, , 353-394. | | 0 |
| 526 | Flow Cytometric Techniques in the Diagnosis and Monitoring of Acute Leukaemias. , 2023, , 47-59. | | 0 |
| 527 | Management of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (Ph-Like ALL). , 2023, , 311-327. | | 0 |
| 528 | Management of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia. , 2023, , 289-310. | | 0 |
| 529 | Immunotherapeutic Targeting of AML. , 2023, , 175-191. | | 0 |
| 530 | Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab. Therapeutic Advances in Hematology, 2023, 14, . | 2.5 | 0 |
| 531 | ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia. Annals of Oncology, 2024, 35, 15-28. | 1.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 532 | Blinatumomab consolidation postâ€“autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. Blood Advances, 2024, 8, 513-522. | 5.2 | 0 |
| 533 | Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission. Blood, 0, , . | 1.4 | 3 |
| 534 | T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphomaâ€”An Update. Journal of Clinical Medicine, 2023, 12, 6737. | 2.4 | 0 |
| 535 | Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia: two-case report. Annals of Hematology, 0, , . | 1.8 | 0 |
| 536 | Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma. Future Oncology, 2023, 19, 2083-2101. | 2.4 | 0 |
| 537 | Case Report: Blinatumomab as upfront consolidation and maintenance therapy in a pediatric patient with high-risk B-cell acute lymphoblastic leukemia. Frontiers in Oncology, 0, 13, . | 2.8 | 1 |
| 538 | CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Medicine, 2023, 12, 6883. | 2.4 | 0 |
| 539 | Blinatumomab Redirects Donor Lymphocytes against CD19+ Acute Lymphoblastic Leukemia without Relevant Bystander Alloreactivity after Haploidentical Hematopoietic Stem Cell Transplantation. International Journal of Molecular Sciences, 2023, 24, 16105. | 4.1 | 0 |
| 540 | Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL. Journal of Clinical Oncology, 2024, 42, 907-914. | 1.6 | 0 |
| 541 | Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study. Clinical Lymphoma, Myeloma and Leukemia, 2024, 24, e59-e66.e2. | 0.4 | 0 |
| 542 | SOHO State of the Art Updates and Next Questions \| Approach to Older Adults With Philadelphia-Chromosome Negative Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2024, 24, 133-140. | 0.4 | 0 |
| 544 | Novel Biomarkers and Molecular Targets in ALL. Current Hematologic Malignancy Reports, 0, , . | 2.3 | 0 |
| 545 | Leveraging health care technology to improve health outcomes and reduce outcome disparities in AYA leukemia. Hematology American Society of Hematology Education Program, 2023, 2023, 573-580. | 2.5 | 0 |
| 546 | The effectiveness of blinatumomab in clearing measurable residual disease in pediatric Bâ€cell acute lymphoblastic leukemia patients detected by nextâ€generation sequencing. Cancer Medicine, 2023, 12, 21978-21984. | 2.8 | 0 |
| 547 | Innovating Simpler and Less Toxic Frontline Management for Adults With ALL. Journal of Clinical Oncology, 0, , . | 1.6 | 0 |
| 549 | Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy. Korean Journal of Internal Medicine, 2024, 39, 34-56. | 1.7 | 0 |
| 550 | Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia. Critical Care, 2024, 28, . | 5.8 | 1 |
| 552 | New immune cell engagers for cancer immunotherapy. Nature Reviews Immunology, 0, , . | 22.7 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 554 | Old rivals become new friends. Blood, 2024, 143, 380-382. | 1.4 | 0 |
| 555 | Successful treatment with blinatumomab for acute lymphoblastic leukemia in an older adult patient complicated with hepatocarcinoma. Leukemia Research Reports, 2024, 21, 100413. | 0.4 | 1 |
| 556 | Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. American Journal of Hematology, 2024, 99, 586-595. | 4.1 | 1 |
| 557 | Liquid biopsy for monitoring minimal residual disease in localized and locally-advanced non-small cell lung cancer after radical-intent treatment. , 2024, 4, 100145. | | 0 |
| 559 | Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab. Annals of Hematology, 2024, 103, 1397-1402. | 1.8 | 0 |
| 560 | Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC). Journal of Clinical Oncology, 0, , . | 1.6 | 0 |
| 561 | Cardiovascular toxicities associated with bispecific T-cell engager therapy. , 2024, 12, e008518. | | 0 |
| 564 | SOHO State of the Art Updates and Next Questions \| Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2024, , . | 0.4 | 0 |
| 565 | Reducedâ€dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed Bâ€cell acute lymphoblastic leukemia. Cancer Medicine, 2024, 13, . | 2.8 | 0 |
| 566 | Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy. Acta Pharmaceutica Sinica B, 2024, , . | 12.0 | 0 |